Should I get whole exome sequencing for my Ovarian Cancer

Whole Exome Sequencing for Ovarian Cancer: What You Should Know

This is an excellent question, and the answer depends on several factors specific to your situation. Let me explain what the evidence shows and what questions to discuss with your oncology team.

What Whole Exome Sequencing (WES) Can Tell You

Whole exome sequencing reads the "instruction manual" of your tumor's genes—specifically the protein-coding regions. For ovarian cancer, this can reveal:

• BRCA mutations (BRCA1/BRCA2) - critical for treatment decisions, as PARP inhibitors are FDA-approved for BRCA-positive ovarian cancers
• Homologous recombination deficiency (HRD) - indicates whether your tumor may respond to PARP inhibitors
• Other actionable mutations - genes that may guide targeted therapy options
• Germline vs. somatic findings - understanding whether mutations are inherited (affecting your family and future screening) or only in the tumor

What the Evidence Shows

According to discussions from leading oncologists and molecular experts, there's an important distinction to understand:

Standard testing vs. comprehensive testing: Many ovarian cancer patients receive targeted gene panels (testing specific genes relevant to ovarian cancer). However, whole exome sequencing provides a broader view. As noted in expert webinars on molecular testing, when doctors only run limited panels, they may miss important mutations that could guide treatment decisions—particularly mutations that appear in whole exome sequencing but not in standard panels.

The key insight: Somatic testing (tumor tissue) is more important than germline testing for immediate treatment decisions, because what matters most is what's happening in YOUR tumor right now, not just inherited mutations.

Practical Considerations

Cost and Coverage:

• WES can be expensive ($1,000-$6,000+ depending on the lab)
• Insurance coverage varies—some plans cover it, others don't
• Ask your oncology team if they'll order it and whether your insurance will cover it

Timing:

• Ideally done early in your diagnosis when you have fresh tumor tissue
• Can sometimes be done on archived tissue, though older samples may have degraded RNA
• Results typically take 2-4 weeks

What happens with the results:

• Your oncologist interprets findings in the context of YOUR specific ovarian cancer type and stage
• Not all mutations found are "actionable" (meaning they don't necessarily change treatment)
• Some findings may be variants of uncertain significance (VUS)—meaning scientists don't yet know what they mean

Questions to Ask Your Oncology Team

1. "Do you recommend whole exome sequencing or a targeted ovarian cancer panel for my case, and why?"

   • Different approaches may be appropriate depending on your stage, histology (type), and treatment goals

2. "Will my insurance cover WES, and if not, what are the out-of-pocket costs?"

   • Get this answer before proceeding

3. "If we find a BRCA mutation or HRD signature, how would that change my treatment plan?"

   • This helps you understand whether the test results will actually impact your care decisions

4. "Should I also get germline (blood) genetic testing, and do I need genetic counseling?"

   • Important for understanding inherited cancer risk and implications for family members

5. "How will you use these results to guide my treatment, and when will we have the results?"

   • Ensures the testing serves a clear purpose in your care plan

The Bottom Line

WES can be valuable for ovarian cancer patients, particularly if:

• You haven't had comprehensive molecular testing yet
• Your tumor type or stage suggests targeted therapy options might be relevant
• You want the most complete picture of your tumor's genetic landscape
• Your insurance will cover it or you can afford it

However, your oncologist should drive this decision based on:

• Your specific ovarian cancer type and stage
• Available treatment options for your situation
• Whether results would actually change your treatment plan
• Practical factors like cost and timing

According to molecular oncology experts, the real value of comprehensive testing comes when it informs actionable treatment decisions—not just for information's sake.

---

Recommended Resources

For more detailed information about ovarian cancer and genetic testing:

• NCCN Guidelines for Ovarian Cancer - includes recommendations on genetic testing
• American Cancer Society - ovarian cancer information and genetic testing guidance
• National Cancer Institute (NCI) - comprehensive ovarian cancer information
• Leukemia & Lymphoma Society - resources on hereditary cancer syndromes

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.